Encore Medical, Inc.

FWP supplemental

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an IPO with an assumed initial public offering price of $5.00 per share, aiming to raise proceeds through the sale of 3,000,000 shares. The filing details the conversion of Series A Preferred Stock into common shares, pro forma capitalization adjustments for the License Agreement, and underwriting terms including an over-allotment option. The company highlights risks related to capital requirements, uncertainty in cash flow projections, and potential changes in the use of offering proceeds. The IPO is contingent on NYSE American listing approval.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an IPO with an initial public offering price of $5.00 per share, underwritten by The Oak Ridge Financial Services Group, Inc. and Network 1 Financial Securities, Inc. The offering includes an over-allotment option for 450,000 additional shares. Proceeds, before expenses, are projected at $13.8M (no over-allotment) or $15.87M (with over-allotment). The company plans to list on NYSE American under the symbol "EMI," though approval is not guaranteed. The offering is contingent on listing approval, and the company faces risks related to market demand, price stabilization activities, and uncertainties in post-lock-up registration processes.

FWP supplemental

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is preparing for its initial public offering (IPO) with a proposed $15 million equity raise, including a 15% over-allotment option. The company focuses on PFO (Patent Foramen Ovale) closure devices to address stroke and migraine markets, with a $1.5B+ stroke opportunity and $100B+ migraine market potential. Clinical trials are underway for both indications, including a pivotal FDA-approved study comparing its device to existing options. The offering includes a license agreement with GB Sciences for AI-driven patient data analysis, aiming to expand market penetration. Proceeds will fund clinical trials, debt repayment, sales, and general operations. The company highlights its differentiated technology, CE marking, and FDA trial progress, with a target listing on NYSE American under ticker EMI.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an IPO with underwriters The Oak Ridge Financial Services Group, Inc. and Network 1 Financial Securities, Inc. The offering includes a public price of $5.00 per share, underwriting discounts of $0.40 per share (8%), and potential proceeds of $15.87M if the over-allotment option is fully exercised. The company plans to use proceeds for working capital and general corporate purposes. The filing details registration statements on Form S-8 and S-1, lock-up agreements for 180 days, and underwriters' warrants exercisable after 1 year. The stock is seeking NYSE American listing, contingent on approval.

FWP supplemental

Price $5.00 · Range $5.00 to $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is preparing for its initial public offering (IPO) with a proposed $15 million offering of 3 million common shares at $5.00 per share. The company develops PFO closure devices for treating patent foramen ovale, a heart defect linked to strokes and migraines. The filing highlights clinical trials for both stroke and migraine indications, with a focus on FDA approval. The company emphasizes its differentiated technology, market opportunities exceeding $1.5 billion for stroke and $100 billion for migraines, and favorable European sales momentum. Proceeds will fund clinical trials, commercial growth, debt reduction, and working capital.

S-1/A amended

Encore Medical, Inc. filed an S-1/A amendment to its registration statement, adding Exhibit 4.3 (2021-2022 Investor’s Warrant) and updating the Filing Fee Table. The amendment delays the effective date of the registration statement, with no substantive changes to the offering details. The filing includes corporate governance documents, legal opinions, and exhibits related to securities offerings and contractual agreements.

FWP supplemental

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is preparing for its initial public offering (IPO) with a proposed $15 million offering, including an over-allotment option. The company focuses on PFO closure devices, targeting a $1.5B+ stroke market and $100B+ migraine market. Clinical trials are underway, including a pivotal FDA-approved study and a migraine trial in Europe. The offering aims to fund clinical trials, commercial growth, debt reduction, and working capital. Key financials show increasing sales and a proforma balance sheet reflecting potential net proceeds.

FWP supplemental

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an initial public offering (IPO) to raise $15 million (plus over-allotment) by issuing 3 million shares at $5.00 per share. The proceeds will fund clinical trials for stroke and migraine indications, commercial growth, debt reduction, and working capital. The company aims to advance its PFO closure device, which has demonstrated superior clinical performance, and seeks FDA approval for both stroke and migraine markets. The offering is listed on NYSE American under ticker EMI.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an IPO to raise capital for clinical development of stroke and migraine indications, working capital, and debt repayment. The company plans to allocate $7.2M for stroke trials, $2M for migraine programs, and use remaining proceeds for commercialization, equipment, and debt obligations. While the IPO proceeds are expected to cover stroke trials and initial milestones, additional capital may be required for migraine development. The offering also includes a potential over-allotment option to increase proceeds.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an amended S-1/A filing to raise approximately $12.7 million (or $14.65 million if underwriters exercise over-allotment) through an IPO at $5.00 per share. The proceeds will fund clinical development for stroke and migraine indications, with $7.2M allocated to stroke trials and $2M to migraine programs. Additional funds will support commercialization, equipment purchases, and repayment of a $1M loan to Merit Medical Systems. The company acknowledges potential need for additional capital to complete migraine trials and emphasizes uncertainty in meeting development timelines.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an IPO to raise capital for clinical development, particularly for stroke and migraine indications, with $7.2 million allocated for stroke trials and $2.0 million for migraine programs. The company expects proceeds to cover clinical trial activities and commercialization efforts but may require additional funding for later-stage migraine trials. The offering aims to strengthen financial flexibility, with net proceeds estimated at $12.96 million (or $14.88 million with full over-allotment), and outlines detailed use-of-proceeds breakdowns and capitalization scenarios.

S-1 filed

Encore Medical, Inc. is conducting an initial public offering (IPO) to raise capital for clinical trials focused on stroke and migraine indications, working capital, and general corporate purposes. The company plans to convert its Series A Preferred Stock into common stock prior to the offering, eliminating associated rights and preferences. The filing highlights risks including reliance on clinical trial outcomes, regulatory changes, litigation exposure, IT system capabilities, compliance requirements, need for additional financing, stock price volatility, and significant dilution for new investors. The company has not paid dividends and does not intend to do so in the foreseeable future.